Mar 11 |
Acelyrin jumps 10% on izokibep psoriatic arthritis results
|
Mar 11 |
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
|
Mar 11 |
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
|
Mar 11 |
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
|
Feb 15 |
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
|
Dec 20 |
ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors
|
Dec 7 |
Acelyrin Looks Interesting Before PsA Data In Q1
|
Nov 28 |
Why Is Inflammation Disease Focused Acelyrin Stock Trading Lower Today?
|
Nov 28 |
Biggest stock movers today: Micron, PDD Holdings, Carlyle Group, Zscaler and more
|
Nov 28 |
5 Things to Know Before Markets Open
|